GIGABYTE
14.12.2022 15:01:34 CET | Business Wire | Press release
GIGABYTE, a leading brand of computer innovations and key player in the tech industry, resumes its strong presence at the upcoming CES (#9119 LVCC North Hall). From January 5th to 8th, GIGABYTE will exhibit its HPC products and total solutions, demonstrating the full breadth of ‘Power of Computing’ and its impact on shaping the technology landscape.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005086/en/
Driving Technology Towards Net Zero, GIGABYTE HPC Solutions Rally ‘Power of Computing’ at CES (Photo: Business Wire)
GIGABYTE is addressing a serious topic that concerns the tech industry on a global scale with its HPC solutions. The data centers in the world account for as much carbon emission as the entire aviation industry while technology continues progressing rapidly in the direction where more computing performance is required to keep up with the innovations. This challenge of balancing computing demand vs carbon footprint can be overcome by optimizing data centers' operation stability and power usage effectiveness using advanced cooling solutions, which is one of the highlighted sections in GIGABYTE's booth. The section features a walkthrough of the mainstream cooling solutions and a display of server products designed to fit in air, direct-liquid, and immersion cooling.
GIGABYTE invested in immersion cooling technology early, and has a monumental breakthrough this year as it released its own-designed immersion cooling tanks that comply with both EIA and OCP specifications. The investment in immersion cooling has come to fruition as GIGABYTE's expertise in the technology was trusted by the world's leading IC foundry giant, which in turn, garnered GIGABYTE's experience and products to propel its advanced process and pursue its ESG leadership and influence.
Vehicle tech is thriving as it leverages the power of computing to helm artificial intelligence and communications, therefore paving way for safer driving and smarter traffic. With extensive experience in developing ADCU (Autonomous Driving Control Unit) and ADAS DCU (Domain Control Unit), GIGABYTE provides the automotive industry with high-performance Zonal Integrated DCUs and decision-making control hosts, which are built with a centralized architecture and can be integrated into various requirements and design concepts, lowering vehicle production costs.
GIGABYTE invited other companies of key components and strategic partnership to exhibit a comprehensive demonstration of a smart car, illustrating the computers' capacity to receive information from multiple signals and process the information in real-time to prompt critical and accurate corresponding commands.
The annual CES remains a landmark event for thought leaders and influencers to come together and pivot future tech evolution. The ‘Power of Computing’ is becoming a prevalent resource that pushes the pedal of the 21st century digital transformation. GIGABYTE brought its data center expertise and industry know-how, from HPC servers, workstations to personal computers, and AI solutions from development platforms to self-driving cars, to empower users from enterprises to individuals to expand their business endeavors and personal visions. GIGABYTE is excited to welcome attendees to visit its booth to connect and move the future together using ‘Power of Computing’.
Visit GIGABYTE ‘Power of Computing’ event page
More information at https://www.gigabyte.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005086/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom